HER2 is a commonly overexpressed receptor responsible for cell migration and apoptotic resistance in breast, gastric, and ovarian carcinomas.65, 66, 67In vivo trials showed the fusion protein to be capable of significantly delaying both HER2-positive non-small cell lung cancer and HER2-positive breast cancer with 1 mg/kg dose.64 This evidence concerns the gene ERBB2 and breast carcinoma.